Overview A global pharmaceutical company was facing regulatory investigations across multiple jurisdictions due to whistleblower allegations concerning corruption within its China operations. The allegations suggested

Overview A global pharmaceutical company with extensive operations in China faced allegations of severe FCPA violations, involving fraudulent expense claims by sales representatives, third-party travel